Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

1.5K

Mechanisms and therapeutic potential of YTHDF readers: Linking epitranscriptomics to cancer

Na Deng1,2, Qiang Sun3,4, Shuying Wang5

  • 1Key Laboratory of Molecular Pathology and Epidemiology of Gastric Cancer in Liaoning Education Department, The First Hospital of China Medical University, Shenyang, 110001, China.

Journal of Pharmaceutical Analysis
|April 6, 2026
PubMed

Insights

YT521-B homology domain-containing family proteins (YTHDFs) are key players in RNA epigenetic modifications like m6A, influencing cancer development and treatment resistance. Targeting YTHDFs offers a promising strategy for effective cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Epigenetics

Background:

  • YT521-B homology domain-containing family proteins (YTHDFs) act as effector proteins for RNA epigenetic modifications.
  • YTHDFs are involved in N6-methyladenosine (m6A), N1-methyladenosine (m1A), and 5-methylcytosine (m5C) modifications.
  • These modifications play critical roles in cancer biology and the maintenance of cancer hallmarks.

Purpose of the Study:

  • To review the regulatory mechanisms and pathological consequences of YTHDFs in tumorigenesis.
  • To explore the role of YTHDFs in therapeutic resistance.
  • To highlight the potential of targeting YTHDFs for cancer therapy.

Main Methods:

  • Literature review of accumulating evidence on YTHDFs.
  • Analysis of YTHDFs' involvement in RNA stability, translation, and metabolism.
  • Examination of YTHDFs' independent RNA epigenetic modification pathways.

Main Results:

  • YTHDFs manipulate RNA stability, translation, and metabolism.
  • YTHDFs influence tumor initiation, progression, and anti-tumor treatment efficacy.
  • YTHDFs are implicated in therapeutic resistance.

Conclusions:

  • YTHDFs are crucial in cancer development and progression.
  • Targeting YTHDFs presents a promising strategy for cancer treatment.
  • YTHDFs offer potential for eliminating tumor cells and improving treatment efficacy.
Keywords:
CancerCancer therapyRNA epigenetic modificationReaderTherapy resistanceYTHDFs

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.2K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K